Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
The HELP Study's findings are the foundation for the oral levosimendan patent. Tenax Therapeutics' patent application for its oral levosimendan, TNX-103, to treat pulmonary hypertension combined with heart failure wit...
Share This Article
Ready-to-post copy includes the article link.
USPTO Grants Notice of Allowance for Tenax Therapeutics' Oral Levosimendan The HELP Study's findings are the foundation for the oral levosimendan patent. Tenax Therapeutics' patent application for its oral levosimendan, TNX-103, to treat pulmonary hypertension combined with heart failure wit... Read the full IIPLA article: https://iipla.org/news/uspto-grants-notice-of-allowance-for-tenax-therapeutics-oral-levosimendan